Kazia Therapeutics Ltd
KZIA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$7.87
KIRA · Stoqly’s AI analyst, in plain words
- Kazia Therapeutics Ltd had $0.0M of revenue in fiscal 2025, down 98.2% on the year before.
- Kazia Therapeutics Ltd lost $13.4M in fiscal 2025.
- Kazia Therapeutics Ltd returned $0.0M to shareholders in fiscal 2025. The diluted share count rose 107.8%.
- Kazia Therapeutics Ltd has $2.6M more cash than debt.
Market cap
—
P/E
—
Revenue
$0.0M
Net income
−$13.4M
Free cash flow
—
Operating margin
—
Kazia Therapeutics Ltd in 30 seconds · fiscal 2025
Are sales growing?
−98.2%
No. Sales fell 98.2% last year.
Does it make a profit?
−49,261.0%
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
What Kazia Therapeutics Ltd does
No business description yet.
- Fiscal year ends
- June 30, 2025
- Latest annual report
- 20-F · Nov 7, 2025
- Legal name
- KAZIA THERAPEUTICS LTD
- CIK
- 0001075880
Kazia Therapeutics Ltd · KZIA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $11.3M | $0.0M | $0.0M | $1.5M | $0.0M |
| Revenue growth | — | −100.0% | — | — | −98.2% |
| Net income | −$6.3M | −$18.1M | −$13.8M | −$17.6M | −$13.4M |
| Net margin | −55.5% | — | — | −1,160.2% | −49,261.0% |
| Diluted EPS | −$0.05 | −$0.14 | −$0.08 | −$0.07 | −$0.02 |
| Cash | |||||
| Cash from operations | −$6.8M | −$16.5M | −$10.2M | −$6.3M | −$8.6M |
| Dividends paid | — | — | $0.0M | $0.0M | $0.0M |
| Share count change | 61.1% | 12.6% | 39.1% | 43.1% | 107.8% |
| Debt and strength | |||||
| Cash and short-term investments | $20.7M | $5.1M | $3.5M | $1.1M | $2.8M |
| Debt incl. finance leases | $0.0M | $1.3M | $1.2M | $0.4M | $0.3M |
| Shareholders' equity | $28.4M | $12.6M | $8.0M | −$6.7M | −$5.4M |
| Current ratio | 3.5x | 1.4x | 1.4x | 0.2x | 0.4x |
| Returns and quality | |||||
| Return on equity | −33.0% | −88.6% | −133.9% | −2,668.2% | — |
| Return on tangible equity | −49.8% | — | — | — | — |
| Piotroski F-score | — | 1 | 2 | 3 | 2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Kazia Therapeutics Ltd · KZIA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $7.87 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001075880). Data updated October 24, 2026. Filed in AUD under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.